Keyphrases
Paclitaxel Chemotherapy
100%
Phase I Study
100%
Metformin
100%
Carboplatin-paclitaxel
100%
Advanced Ovarian Cancer
100%
Recommended Phase 2 Dose
60%
Carboplatin
30%
Area under the Concentration-time Curve
20%
Paclitaxel
20%
Dose-limiting Toxicity
20%
Dose Level
20%
Ovarian Cancer
20%
Adverse Events
20%
Metabolic Genotype
20%
Plasma Parameters
10%
Serum Samples
10%
Pharmacokinetics
10%
Cancer Model
10%
Anticancer Activity
10%
Fixed-dose Combination
10%
Chemotherapy Administration
10%
Hypomagnesemia
10%
Diarrhea
10%
Diabetic Patients
10%
Targeted Agents
10%
Thrombocytopenia
10%
Pharmacokinetic Analysis
10%
Cancer Risk
10%
Treatment Cycle
10%
Epithelial Ovarian Cancer
10%
Anemia
10%
Pharmacokinetic Interaction
10%
Epidemiological Study
10%
Metformin Use
10%
Therapeutic Range
10%
Common Terminology Criteria for Adverse Events (CTCAE)
10%
Neoadjuvant
10%
Plasma Samples
10%
Single Center
10%
Leukopenia
10%
Pharmacology, Toxicology and Pharmaceutical Science
Paclitaxel
100%
Ovary Carcinoma
100%
Chemotherapy
100%
Carboplatin
100%
Metformin
100%
Drug Metabolism
100%
Pharmacokinetics
27%
Ovary Cancer
27%
Drug Metabolizing Enzyme
20%
Drug-Drug Interaction
20%
Glutathione
20%
Ciclosporin
20%
Comorbidity
20%
Pharmacogenomics
20%
Drug Metabolite
20%
Cohort Study
20%
Adverse Event
18%
Malignant Neoplasm
9%
Thrombocytopenia
9%
Cancer Model
9%
Anemia
9%
Hypomagnesemia
9%
Leukopenia
9%
Diarrhea
9%
Diabetes Mellitus
9%